Drug Profile


Alternative Names: BST-4001; K-163; K163SZ; Pyridorin; Pyridoxamine dihydrochloride

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioStratum
  • Developer Kowa; NephroGenex
  • Class Picolines; Small molecules
  • Mechanism of Action Advanced glycosylation end product inhibitors; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic nephropathies

Highest Development Phases

  • Phase I Schizophrenia
  • Preclinical Acute kidney injury
  • Suspended Diabetic nephropathies

Most Recent Events

  • 03 Jan 2017 Phase-I clinical trials in Schizophrenia in Japan (unspecified route) (Kowa Pharmaceuticals pipeline, January 2017)
  • 29 Mar 2016 NephroGeneX has patent protection for pyridoxamine in USA, Canada and Europe (NephroGeneX 10-K; March 2016)
  • 29 Mar 2016 NephroGeneX has patents pending for pyridoxamine in USA (NephroGeneX 10-K; March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top